NanoPass Technologies
NanoPass Technologies is an Israeli medical device company developing the MicronJet™ MEMS-based hollow silicon crystal microneedle platform for virtually pain-free intradermal delivery. It serves aesthetic physicians and pharmaceutical/biotech companies across 30+ countries via distribution partners and licensing.
- Company typePrivate
- Founded2002
- HeadquartersNess Ziona, Israel
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What NanoPass Technologies does
NanoPass Technologies Ltd. is a privately held Israeli medical device company founded in 2002 and headquartered in Ness Ziona, Israel. The company develops and commercializes the MicronJet™ intradermal delivery platform — a hollow silicon crystal microneedle device manufactured using MEMS (Micro Electro Mechanical Systems) semiconductor-grade processes. The platform comprises MicronJet™ 600 (0.6mm, three micro-pyramids, flow equivalent to a 30G needle) for standard aesthetic, vaccine, and therapeutic applications, and MicronJet™ 800 (0.8mm, flow equivalent to a 27G needle) optimized for higher-viscosity formulations and hair restoration, launched in January 2026. NANOSOFT™, a private-label co-branded device with FILLMED, extends the platform into aesthetics in 60+ countries.
NanoPass serves two primary customer segments: medical aesthetics (aesthetic physicians, dermatologists, and clinics using the device for skin boosters, Botox, PRP, mesotherapy, dermal fillers, and lidocaine) and pharmaceutical/biotechnology companies (vaccine developers, immunotherapy researchers, and biologic drug developers seeking dose sparing and improved immunogenicity). Revenue is generated through hardware sales of MicronJet™ devices via direct B2B sales and a network of exclusive regional distribution partners, supplemented by licensing and private-label/co-branding arrangements (e.g., NANOSOFT™ with FILLMED).
The company operates in over 30 countries with regulatory approvals in major markets including the US (FDA), EU (CE), Canada, China (NMPA), Brazil (ANVISA), Korea (KFDA), Russia, Turkey, Australia, and Hong Kong. Distribution is primarily channel-led: Crescita Therapeutics holds exclusive rights for Canada, Aesthetic Management Partners (AMP) for the US, and YNC Medical for China (where more than 10,000 doctors have been trained). Manufacturing is anchored by a longstanding foundry relationship with Micro2Nano (M2N). Backed by West Pharmaceutical Services (strategic investor since 2016) and Awz Ventures (lead investor in the July 2024 $6M round), NanoPass reports a clinical evidence base of 70+ trials, 30,000+ injections, and ~7,500 patients.
NanoPass Technologies firmographics
Firmographics- Name
- NanoPass Technologies
- Legal name
- NanoPass Technologies Ltd.
- Website
- https://nanopass.com
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- NanoPass Technologies is an Israeli medical device company developing the MicronJet™ MEMS-based hollow silicon crystal microneedle platform for virtually pain-free intradermal delivery. It serves aesthetic physicians and pharmaceutical/biotech companies across 30+ countries via distribution partners and licensing.
- Ownership category
- akta.pro rank
NanoPass Technologies industry classification
Industry- Product category
- Medical Devices (Intradermal Delivery / Microneedle)
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Needle-Free Injection Systems (Jet Injectors/Microneedle Patches) (HLAHAIAD)
- akta.pro secondary industry
- Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral) (HLAAAEAF)
Keywords
Where NanoPass Technologies is headquartered
LocationHeadquarters
- HQ city
- Ness Ziona
- HQ country
- Israel
- HQ region
- Middle East
Offices1 record
Markets served
NanoPass Technologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- Medical Device Sales: NanoPass generates revenue primarily through the sale of its MicronJet™ intradermal delivery devices (MicronJet™ 600 and MicronJet™ 800) via direct commercial sales and distribution partnerships across over 30 countries.
- Licensing and Co-branding: NanoPass licenses its microneedle technology to aesthetic and pharmaceutical partners through private label agreements. Examples include NANOSOFT™ with FILLMED for aesthetics. The company also grants non-exclusive device access to pharmaceutical partners for clinical supply (e.g., Immune Design for oncology immunotherapy).
- Distribution Agreement Revenue: NanoPass expands market reach through exclusive distribution agreements with regional partners such as Crescita (Canada) and AMP (USA), generating revenue through product sales to these channel partners.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | MicronJet™ 600 (0.6mm) — for skin rejuvenation, scars, pigmentation, hyperhidrosis, local anesthesia |
| Other | Multi-year contract | MicronJet™ 800 (0.8mm) — optimized for high-viscosity formulations and hair restoration treatments |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels5 records
NanoPass Technologies product offering
Product offeringCore offering
NanoPass Technologies designs, manufactures, and commercializes the MicronJet™ intradermal delivery platform — MEMS-based hollow silicon crystal microneedle devices available in 0.6mm (MicronJet™ 600) and 0.8mm (MicronJet™ 800) variants. These devices deliver therapeutics, vaccines, and aesthetic products shallow into the dermis with high consistency and minimal pain. NanoPass sells directly to pharma/biotech companies for clinical co-development and to aesthetic physicians/dermatologists, and distributes via exclusive regional partners across 30+ countries.
Product overview
NanoPass Technologies offers the MicronJet™ intradermal delivery product platform, consisting of hardware-based microneedle devices for intradermal injection. The platform includes two primary products: MicronJet™ 600 (0.6mm) for standard aesthetic, vaccine, and therapeutic applications; and MicronJet™ 800 (0.8mm) for higher viscosity formulations and hair restoration treatments. Both devices leverage MEMS technology with silicon crystal delivery pyramids. The company also offers NANOSOFT™, a private-label version co-branded with FILLMED for aesthetic use. All products enable consistent, virtually pain-free intradermal delivery of substances approved for this route.
Differentiator
Problem solved
Functional benefit
Brands
- MicronJet: Intradermal delivery device platform featuring hollow silicon crystal microneedles for pain-free drug and vaccine delivery, including MicronJet 600 (0.6mm) and MicronJet 800 (0.8mm) models
- NANOSOFT
Products and services
- MicronJet™ 600 A 0.6mm intradermal delivery device with three hollow pyramid-shaped silicon crystal microneedles manufactured using semiconductor-grade MEMS technology. Designed for consistent, virtually pain-free delivery of aesthetic formulations, vaccines, and therapeutics. Suitable for skin rejuvenation, scars, pigmentation, hyperhidrosis, local anesthesia, and vaccine dose sparing. Flow rate equivalent to a 30-gauge needle.
- MicronJet™ 800 A 0.8mm intradermal delivery device with three hollow pyramid-shaped silicon crystal microneedles optimized for medium-to-high viscosity formulations. Flow rate equivalent to a 27-gauge needle while maintaining precise intradermal depth. Particularly suited for hair restoration treatments, thicker skin areas, and applications requiring higher viscosity delivery.
- NANOSOFT™ A private label, co-branded version of the MicronJet microneedle device developed with FILLMED (Laboratoires Filorga Medical) for use with NCTF® 135 HA polyrevitalizing solution in aesthetic treatments. Features three 0.6mm hollow pyramid-shaped microneedles produced using MEMS technology for nearly painless, shallow intradermal delivery. Distributed by FILLMED in over 60 countries.
Quantifiable outcome
- 99% bleb formation rate (>6mm) across over 1,000 injections on more than 800 subjects
- +5 more outcomes
Companies that use NanoPass Technologies
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles3 records
NanoPass Technologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
NanoPass Technologies partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core, major and minor.
- Distribution Partners (Singapore, Mexico, Colombia, Australia)coreNanoPass signed four new distribution agreements in November 2025 expanding commercial presence into Singapore, Mexico, Colombia, and Australia. These additions brought the total country coverage to over 30 countries, joining 28 channels established in the prior year across the US, Canada, Italy, France, Spain, and the UK.
- Crescita Therapeutics Inc.coreCrescita Therapeutics signed an exclusive distribution agreement with NanoPass to launch and distribute the MicronJet™ 600 intradermal injection device in Canada, pending Health Canada approval expected in H1 2025. Crescita is a growth-oriented Canadian commercial dermatology company (TSX: CTX, OTC: CRRTF).
- YNC MedicalmajorYNC Medical is the premier partner of NanoPass in the medical market in China. YNC has worked with KOLs in more than 20 provinces and conducted training and academic communications with over 10,000 doctors and medical workers, supporting NanoPass's intradermal delivery platform and research institutions.
- EmergexmajorEmergex initiated a Phase I clinical study (naNO-COVID) using NanoPass's MicronJet® 600 for its synthetic T-cell adaptive COVID-19 vaccine. The partnership demonstrates that MicronJet™ can reduce vaccine doses and improve immune responses across vaccine platforms including mRNA, viral vectors, and proteins.
- Micro2Nano (M2N)coreNanoPass and M2N entered a strategic development and foundry agreement for the design and production of NanoPass's proprietary MEMS-based microneedles. M2N has been integral to NanoPass's manufacturing since 2007, providing high-quality foundry services, ingenuity, and quick turnaround on development projects.
- Aesthetic Management Partners (AMP)coreAMP and NanoPass signed an agreement to commercialize MicronJet® 600 intradermal delivery device in the US aesthetic market. The partnership provides dermatologists and aesthetic physicians with a safe, nearly painless, shallow, and consistent intradermal delivery device.
- FILLMED (Laboratoires Filorga Medical)majorFILLMED and NanoPass signed a private label agreement to co-brand NanoPass's microneedle device as NANOSOFT™ for use with FILLMED's NCTF® 135 HA polyrevitalizing solution for aesthetic treatments. NANOSOFT™ was launched in Europe in May 2019 following AMWC Monaco. FILLMED distributes in over 60 countries.
- IDRI (Infectious Disease Research Institute)majorIDRI and NanoPass signed a collaboration agreement to develop and test a Zika vaccine using replicating viral RNA (rvRNA) construct administered intradermally via MicronJet™. This builds on nearly a decade of collaboration on multiple global health vaccine programs. IDRI received $491,000 in NIH funding for the Zika vaccine development.
- Immune DesignmajorNanoPass entered a clinical supply and support agreement to provide MicronJet™ for use with Immune Design's oncology immunotherapy products from its ZVex discovery platform. The non-exclusive agreement covers all of Immune Design's cancer immunotherapy programs globally.
- CircassiaminorCircassia licensed NanoPass's MicronJet™ microneedle intradermal delivery system for use with its ToleroMune Allergy T-Cell Vaccines (cat, ragweed, and other allergy therapies). The partnership aimed to enhance allergy immunotherapy delivery by targeting the skin's high concentration of antigen-presenting cells.
Scale indicators5 records
Recent moves8 records
Expansion highlights6 records
NanoPass Technologies competitors and assessment
Company assessmentDirect peers
- Vaxxas: Vaxxas develops high-density microarray patch (HD-MAP) technology for needle-free vaccine and biologic delivery. It is the most direct intradermal vaccine delivery peer to NanoPass's MicronJet, targeting the same pharmaceutical partners and global health use cases.
- PharmaJet: PharmaJet markets FDA-cleared needle-free jet injector systems (Tropis, Stratis) for intradermal and intramuscular vaccine delivery. It competes directly with MicronJet in dose-sparing intradermal vaccine applications and is also backed by WHO/PATH for global health deployment.
Broad incumbents
- Becton, Dickinson and Company (BD): BD is a global medical device giant with an intradermal injection device (BD Soluvia) used for flu vaccine delivery and broad pharmaceutical systems / prefilled syringe offerings. It represents the scaled incumbent alternative to NanoPass's MicronJet for intradermal delivery.
- West Pharmaceutical Services: West Pharma is the global leader in injectable drug containment and delivery components and is a strategic investor in NanoPass. It offers elastomeric components, prefilled syringe systems, and auto-injector platforms overlapping with NanoPass's intradermal delivery focus.
- Kindeva Drug Delivery (formerly 3M Drug Delivery Systems): Kindeva is a leading contract drug delivery developer with microneedle and transdermal capabilities inherited from 3M. It serves as a broad incumbent developing microneedle-based drug and vaccine delivery solutions for pharma partners, competing for similar pharmaceutical R&D collaborations.
- LTS Lohmann Therapie-Systeme: LTS Lohmann is a German-headquartered leader in transdermal therapeutic systems and microneedle-based drug delivery. It is a broad incumbent that develops and manufactures microneedle patches for pharmaceutical partners, overlapping with NanoPass's therapeutic and vaccine delivery applications.
Emerging players
- Corium (now part of Gurnet Point / Lotte): Corium pioneered commercial microneedle-based transdermal drug delivery (e.g., transdermal sumatriptan, Corplex technology). It is an emerging player whose microneedle patch technology overlaps with NanoPass's intradermal delivery mission, particularly in CNS and other therapeutic areas.
- Micron Biomedical: Micron Biomedical develops dissolvable microneedle technology for vaccines (including measles-rubella, influenza, and polio) supported by Bill & Melinda Gates Foundation. It is an emerging peer directly competing for the same global health dose-sparing vaccine opportunity as NanoPass.
- Debiotech: Debiotech is a Swiss medical device company developing MEMS-based microneedle and patch-based drug delivery systems. It overlaps with NanoPass's hollow microneedle technology and pharmaceutical partnership model.
- Zosano Pharma: Zosano Pharma develops microneedle transdermal delivery systems (its intracutaneous microarray patch technology) for therapeutic indications including migraines. It is an emerging player using microneedle patches for systemic drug delivery, comparable in modality to NanoPass's intradermal delivery platform.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
NanoPass Technologies social profiles
Digital presenceNanoPass Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
NanoPass Technologies leadership team
Management profileNumber of profiles
Profiles8 records
NanoPass Technologies funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NanoPass Technologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NanoPass Technologies
What does NanoPass Technologies do?
NanoPass Technologies designs, manufactures, and commercializes the MicronJet™ intradermal delivery platform — MEMS-based hollow silicon crystal microneedle devices available in 0.6mm (MicronJet™ 600) and 0.8mm (MicronJet™ 800) variants. These devices deliver therapeutics, vaccines, and aesthetic products shallow into the dermis with high consistency and minimal pain. NanoPass sells directly to pharma/biotech companies for clinical co-development and to aesthetic physicians/dermatologists, and distributes via exclusive regional partners across 30+ countries.
Is NanoPass Technologies a public or private company?
NanoPass Technologies is a private company. It is classified as venture growth investor backed and is currently operating.
When was NanoPass Technologies founded?
NanoPass Technologies was founded in 2002. It employs 1 to 10 people.
Where is NanoPass Technologies based?
NanoPass Technologies is headquartered in Ness Ziona, Israel, in the Middle East region.
How does NanoPass Technologies make money?
Three revenue lines are on record. Medical Device Sales are the primary driver. The others are licensing and Co-branding and distribution Agreement Revenue.
Who are NanoPass Technologies's main competitors?
Direct peers on record are Vaxxas and PharmaJet. Broad incumbents are Becton, Dickinson and Company (BD), West Pharmaceutical Services, Kindeva Drug Delivery (formerly 3M Drug Delivery Systems) and LTS Lohmann Therapie-Systeme. Emerging players are Corium (now part of Gurnet Point / Lotte), Micron Biomedical, Debiotech and Zosano Pharma.
Does NanoPass Technologies have an API?
No public API is recorded for NanoPass Technologies.
What industry is NanoPass Technologies in?
NanoPass Technologies's product category is Medical Devices (Intradermal Delivery / Microneedle). Its primary akta.pro industry code is HLAHAIAD, Needle-Free Injection Systems (Jet Injectors/Microneedle Patches), with a secondary code of HLAAAEAF, Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral). Its NAICS code is 339112 and its SIC code is 3841.